The use of a new subretinal injection device (RetinaJect TM Subretinal Cannula, SurModics, Inc., Eden Prairie, MN) to access the subretinal space in the canine model was evaluated. Subretinal injections were performed in 33 mongrel dogs between 2 and 52 months of age (median = 9 months). In 5 normal dogs the injection of 150 µl saline or India ink occurred by using a conventional subretinal injection device (CSID) with a 30-gauge anterior chamber irrigating cannula. The sclera had to be surgically exposed and penetrated before the subretinal injection with the CSID could occur. After removing the CSID, the conjunctiva over the sclerotomy site had to be closed. In a second group of 28 dogs [16 normals, 10 RPE65 mutants, and 2 with progressive rod cone degeneration (prcd)], the 25-gauge needle of the RetinaJect TM was used to penetrate the conjunctiva and the sclera. Once the tip of the needle was close to the retinal surface, a 39-gauge polyimide cannula was extended and brought into apposition with the retina for the subsequent subretinal injection of 150 µl saline, India ink, or adeno-associated virus (AAV). No closure of the conjunctiva was required. The animals were clinically monitored between 1 and 59 weeks after surgery. From this second group 25 eyes were harvested for routine histological analysis either immediately after surgery or after a clinical observation time of between 1 and 40 weeks. Both devices provided equally successful access to the subretinal space. The main advantage of the RetinaJect TM was that no surgical dissection was required; this led to a shorter procedure time and milder postoperative conjunctival swelling. In summary, the use of the RetinaJect TM can be recommended as an alternative to the CSID for subretinal injections in dogs.
INTRODUCTION
gauge, blunt-tipped cannula for subretinal injections in dogs (5). Recently, we (S.V. and E.dJ.) developed a new device (RetinaJect TM Subretinal Cannula, SurModics, Subretinal injections have been used for the application of drugs, cells, and gene therapy vectors. In order Inc., Eden Prairie, MN) for subretinal injections that permits more efficient and easier access to the subretinal to reach photoreceptor or retinal pigment epithelial (RPE) cells with an agent, subretinal application is required (7, space. The purpose of this study was to evaluate the RetinaJect TM Subretinal Cannula for the subretinal injec-9,13). Successful gene therapy of inherited retinal degenerations by subretinal injection has been described in tions in dogs. Outcome measures were successful acute subretinal bleb formation and degree of ocular inflamvarious animal models, including the Royal College of Surgeons (RCS) rat (11, 14) , the retinal degeneration mation during the first week after surgery. (rd) mouse (6, 8) , and the retinal degeneration slow (rds) mouse (4). Our group, together with other collaborators,
MATERIALS AND METHODS has reported the successful gene replacement therapy in
Animals and Anesthesia a dog model for Leber congenital amaurosis with an RPE65 mutation (1, 2) .
All procedures in this study were approved by the Institutional Animal Care and Use Committee of the Various techniques and devices have been described for subretinal injections (5,13). In the past, our group University of Pennsylvania, and were done in accordance with the ARVO Statement for the Use of Animals has used a custom-built injection device with a small-in Ophthalmic and Vision Research. Mongrel dogs bemg/kg SQ q12 h) and nonsteroidal anti-inflammatories (carprofen 2 mg/kg PO q12 h) were administered before tween 2 and 52 months of age (median = 9 months) were used (Tables 1 and 2 ). Of the 33 dogs, 21 animals were and continued for 2 days after surgery. The dogs were premedicated for anesthesia with atronormal (2 with few retinal folds), 10 dogs were RPE65 mutants, and 2 dogs were affected by progressive rodpine sulfate (0.02-0.04 mg/kg SQ) and acepromazine maleate (0.5 mg/kg SQ). Anesthesia was induced with cone degeneration (prcd) (3) ( Tables 1 and 2 ). The animals were injected subretinally in either one or both eyes.
IV thiopental sodium (20-30 mg/kg). The dogs were intubated, and inhalation anesthesia was maintained with Some of the unilaterally injected dogs were injected in the contralateral eye 1 week later (Tables 1 and 2 ). a gas mixture of isoflurane and oxygen on a semiclosed system. Intravenous fluid (0.9% sodium chloride, 10 ml/ Topical anti-inflammatory premedication consisted of prednisolone acetate 1% and flurbiprofen 0.03% adkg/h) was administered during the surgery. ministered every 30 min during the 2-h time period bePreparation of Eye for Subretinal Injection fore surgery. Mydriasis was achieved with topical tropicamide 1%, phenylephrine 10%, and atropine 1%. For
The globe was positioned by retrobulbar injection of 0.9% sodium chloride (volume to effect), and by nylon survival surgery, systemic antibiotics (amoxicillin 10 stay suture (5-0 Ethilon, Ethicon, Somerville, NJ) pore filter before use. The CSID was removed and the conjunctiva closed in a simple continuous pattern with placed in the ventral sclera next to the limbus. The eye was aseptically prepared with 0.5% diluted povidonepolyglactin 910 suture (7-0 Vicryl, Ethicon). When performed, the lateral canthotomy was closed with nylon iodine solution, and topical proparacaine 0.5% was applied for additional analgesia. In order to improve access suture (5-0 Ethilon). to the globe, the palpebral fissure was kept open with a RetinaJect TM Subretinal Cannula lid speculum, and in smaller dogs, a lateral canthotomy had to be performed for better access. A surgical microThe RetinaJect TM is comprised of a 25-gauge needle scope was brought in position and used for the entire for penetrating the conjunctiva and sclera (Fig. 1B) . This surgery. Aqueous paracentesis with a 30-gauge needle needle is mounted on a hand piece and contains a 39-was done at the limbus, and 150 µl of aqueous humor gauge polyimide cannula mounted in larger silicone tubremoved. An ocular Machemer magnifying vitrectomy ing. The polyimide cannula is attached to a slider within lens (OMVI; Ocular Instruments, Inc., Bellevue, WA) the handpiece, allowing it to be advanced through the placed on the cornea was used to visualize the retina for 25-gauge needle. A Luer adapter is located at the end of the subretinal injections.
the silicone tubing and allows the connection of a syringe or other infusion device (Fig. 1B) .
Conventional Subretinal Injection Device (CSID)
For injection, dissection of the conjunctiva and sclera was not required. The globe was penetrated with the 25-The CSID is shown in Figure 1A . A 30-gauge Knolle gauge needle of the RetinaJect TM 6 mm posterior to limanterior chamber irrigating cannula was connected to a bus, and the tip of the needle was brought into proximity modified plastic tuberculin syringe containing the reof the retinal surface. Using the slider in the hand piece, agent to be injected and a rubber plunger. This syringe the 39-gauge cannula of the RetinaJect TM was extended was connected through flexible extension tubing to a from the tip of the 25-gauge needle and brought tangensecond tuberculin syringe containing 0.9% sodium chlotially into contact with the retina followed by the brisk ride (saline) and operated by an assistant. The lateral injection of 150 µl of saline, India ink, or adeno-associsclera was exposed, by dissecting the overlying conjuncated virus (AAV) ( Table 2 ). The RetinaJect TM was retiva and Tenon's capsule, and focally cauterized. Both moved. Except for the lateral canthotomy (if performed) sclera and pars plana were penetrated perpendicularly no closure was necessary. with a 25-gauge needle, 6 mm posterior to the limbus (10) . The needle was removed and the 30-gauge cannula Postoperative Management of the CSID was inserted through the sclerotomy site into the vitreous. The blunt tip of the cannula was tanSome dogs were euthanized immediately at the conclusion of surgery, and others were recovered and obgentially brought into contact with the retina, and 150 µl of either saline or India ink was briskly injected (Taserved for 1 week or longer after the subretinal injection. At 1 week some of the unilaterally injected dogs were ble 1). India ink was filtered through a 0.45-µm mini- anesthetized again for subretinal injection of the contrathe continuation of both systemic amoxicillin and carprofen for 2 days (same dosages as before surgery), and topilateral eye and euthanized following the second procedure (Tables 1 and 2). cal prednisolone acetate 1% and atropine 1% were used for 1 week as needed to control mild postoperative uveitis. In the survival surgery, 5 mg of triamcinolone acetonide was injected subconjunctivally before recovery from Histologic Evaluation anesthesia, and an antibiotic-steroid ointment (NeomycinPolymyxin B-Dexamethasone 0.1% ointment) was used
In addition to the clinical evaluation, histologic studies were performed in 34 eyes of 18 dogs (Tables 1 and  topically 2). These dogs were euthanized with an IV overdose of sodium pentobarbital. The eyes were enucleated and fixed either in Bouin solution for paraffin embedding or in 4% paraformaldehyde solution for embedding in Optimal Cutting Temperature (OCT) compound. The globes were processed routinely and sectioned through the subretinal injection areas. Paraffin sections were stained with hematoxylin and eosin (H&E).
RESULTS
A total of 9 eyes in 5 dogs were injected with the CSID while 46 eyes in 28 dogs were injected with the RetinaJect TM . All 5 dogs treated with the CSID were normal and were between 2 and 7 months of age (median = 2 months) ( Table 1) . Using the CSID, 4 eyes were injected with saline and 5 with India ink. Of these 9 injected eyes, 2 were followed for 1 week and 7 were harvested immediately after the subretinal injection (Table 1). Because the 100% success rate matched our previous experience on 29 eyes (1) , no additional dogs were injected with the CSID.
Of the 28 dogs injected with the RetinaJect TM , 16 ani- 10 were RPE65 mutants, and 2 were affected by prcd. The dogs of the RetinaJect TM group were between 2 and jection devices. No signs of inflammation were visible 1 week postinjection. Histologically, no difference could 52 months of age (median = 10 months) (Tab. 2). Using the RetinaJect TM , saline was injected in 15 eyes, India be observed between the two techniques (Fig. 3) . While limbal-based conjunctival flaps had to be disink in 2 eyes, and AAV in 29 eyes. Of these 46 injected eyes, 8 were collected immediately after surgery, 2 each sected and then closed in all the eyes in which the CSID was used, no surgical dissection and closure where rewere removed at 1 and 2 weeks postinjection, and the remaining 34 eyes were monitored clinically between 5 quired for the application of the RetinaJect TM . This meant that the surgery time was shorter for the Retina and 59 weeks (Table 2) . Of these latter eyes, 2 were collected after 5 weeks, 8 after 8 weeks, and 3 after Ject TM compared to the CSID; however, surgery times were not measured quantitatively. The injection of India 40 weeks; the remaining eyes are still being monitored clinically as part of a separate study (Table 2) . Except ink with the RetinaJect TM revealed less leakage from the subretinal bleb into the vitreous than with the CSID. for the technical outcome measures of this study, the results of the AAV injections will be reported elsewhere.
Subjectively, the retinotomy sites appeared smaller after injection with the RetinaJect TM than with the CSID but Comparison of RetinaJect TM With CSID this could not be confirmed histologically. The success rate of the subretinal injections was the Other Findings same with both devices. Subretinal blebs were visible in all eyes immediately after the injection (Fig. 2) , and no
The injected subretinal fluid was absorbed and the retinas reattached within 24-48 h. Histologically, the signs of ocular discomfort were observed in any of the operated animals. While chemosis was mild in all eyes subretinal blebs were only visible if the eyes were harvested immediately after the injection (Fig. 3) . One after surgery, the conjunctival swelling appeared less with RetinaJect TM than with CSID. Clinical signs of ocuweek after the subretinal injection, no signs of subretinal fluid could be seen clinically or histologically (Fig. 4) . lar inflammation were mild and similar for the two in- With each injection device sub-RPE injections were these is the fact that RetinaJect TM allows combining multiple steps of the surgery. Conjunctiva, Tenon's capsule, observed histologically in one eye (Tables 1 and 2, Fig.  5 ). Because the injections were placed in the tapetal resclera, and pars plana were penetrated with the 25-gauge needle, which also protected the sensitive 39-gauge cangion, where the RPE lacks pigmentation, the difference between the subretinal and sub-RPE injections could not nula inside. Once the tip of the needle was close to the retinal surface, the 39-gauge cannula could be extended be appreciated, either during surgery or by ophthalmoscopy after the procedure.
with a slider for the subsequent subretinal injection. This approach was less traumatic, and no closure of surgical We noted clinical signs indicating loss of retinal function (negative menace response, pupillary light rewounds was required. The number of eyes injected with the CSID was flexes, and dazzle reflex) 1 day after the injection of India ink. Histologic evaluation confirmed the generalsmaller than the number injected with the RetinaJect TM . Because the CSID was previously successfully used for ized retinal degeneration (Fig. 6) .
29 surgeries on RPE65 mutant eyes (1) , and the results DISCUSSION were identical to the ones listed here, we did not consider it necessary to operate more dogs. This study showed the same effectiveness of subretinal injections in dogs using either the RetinaJect TM or New treatment options for inherited retinal degenerations, such as gene therapy, will soon enter clinical the CSID. However, there were advantages when using the RetinaJect TM compared to the CSID. Chief among trials. For some of these new treatments subretinal injec-
